Sibrafiban versus aspirin to yield maximum protection from ischaemic heart events post acute coronary syndromes (the SYMPHONY trial)
Dr Ho, David Sai Wah (Principal investigator)
Professor Lau Chu Pak (Co-Investigator)
post acute coronary syndromes (the SYMPHONY trial), Sibrafiban versus aspirin
Others - Medicine, Dentistry and Health
Other Funding Scheme
To compare the efficacy, safety, and tolerability of sibrafiban in two dose regimens to that of aspirin in patients following an episode of acute coronary syndrome (ACS) (i.e. Q-wave myocardial infarction (MI), non-Q-wave MI, or unstable angina).